News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
795,261 Results
Type
Article (59873)
Company Profile (710)
Press Release (734655)
Multimedia
Podcasts (157)
Webinars (26)
Section
Business (217885)
Career Advice (2837)
Deals (37662)
Drug Delivery (157)
Drug Development (87215)
Employer Resources (189)
FDA (18053)
Job Trends (16125)
News (372231)
Policy (37300)
Tag
2027 BioCapital Elite (1)
2027 Biotech Bay Standard (2)
2027 Genetown Elite (2)
2027 Genetown Standard (1)
2027 Pharm Country Elite (1)
2027 Pharm Country Premier (1)
2027 Pharm Country Standard (4)
Academia (2970)
Academic (1)
Accelerated approval (46)
Adcomms (34)
Allergies (174)
Alliances (53766)
ALS (209)
Alzheimer's disease (1875)
Antibody-drug conjugate (ADC) (431)
Approvals (18321)
Artificial intelligence (698)
Autoimmune disease (251)
Automation (53)
Bankruptcy (391)
Best Places to Work (12424)
BIOSECURE Act (23)
Biosimilars (221)
Biotechnology (454)
Bladder cancer (186)
Brain cancer (74)
Breast cancer (731)
Cancer (5722)
Cardiovascular disease (506)
Career advice (2410)
Career pathing (47)
CAR-T (329)
CDC (68)
Celiac Disease (2)
Cell therapy (890)
Cervical cancer (45)
Clinical research (74637)
Collaboration (2120)
Company closure (5)
Compensation (1340)
Complete response letters (92)
COVID-19 (2998)
CRISPR (110)
C-suite (1086)
Cystic fibrosis (160)
Data (7358)
Decentralized trials (3)
Denatured (46)
Depression (177)
Dermatology (70)
Diabetes (583)
Diagnostics (7316)
Digital health (56)
Diversity (12)
Diversity, equity & inclusion (47)
Drug discovery (345)
Drug pricing (237)
Drug shortages (37)
Duchenne muscular dystrophy (286)
Earnings (94940)
Editorial (69)
Employer branding (21)
Employer resources (163)
Events (127286)
Executive appointments (1110)
FDA (21682)
Fibrodysplasia Ossificans Progressiva (7)
Friedreich's ataxia (14)
Frontotemporal dementia (33)
Funding (1755)
Gene editing (236)
Generative AI (67)
Gene therapy (742)
GLP-1 (1169)
Government (5317)
Grass and pollen (7)
Guidances (402)
Healthcare (20550)
HIV (80)
Huntington's disease (58)
IgA nephropathy (98)
Immunology and inflammation (320)
Immuno-oncology (94)
Indications (164)
Infectious disease (3352)
Inflammatory bowel disease (221)
Inflation Reduction Act (17)
Influenza (140)
Intellectual property (287)
Interviews (502)
IPO (17466)
IRA (58)
Job creations (4079)
Job search strategy (1984)
JPM (72)
Kidney cancer (19)
Labor market (99)
Layoffs (633)
Leadership (45)
Legal (9217)
Liver cancer (106)
Longevity (28)
Lung cancer (760)
Lymphoma (419)
Machine learning (56)
Management (63)
Manufacturing (1031)
MASH (188)
Medical device (14896)
Medtech (14982)
Mergers & acquisitions (21386)
Metabolic disorders (1566)
mRNA (217)
Multiple sclerosis (185)
NASH (21)
Neurodegenerative disease (430)
Neuropsychiatric disorders (115)
Neuroscience (3414)
Neurotech (1)
NextGen: Class of 2026 (7391)
Non-profit (5014)
Now hiring (74)
Obesity (765)
Opinion (343)
Ovarian cancer (201)
Pain (252)
Pancreatic cancer (274)
Parkinson's disease (370)
Partnered (35)
Patents (587)
Patient recruitment (643)
Peanut (64)
People (63042)
Pharmaceutical (118)
Pharmacy benefit managers (36)
Phase 1 (23282)
Phase 2 (32636)
Phase 3 (24399)
Pipeline (7588)
Policy (359)
Postmarket research (3008)
Preclinical (10069)
Press Release (71)
Prostate cancer (294)
Psychedelics (59)
Radiopharmaceuticals (336)
Rare diseases (1114)
Real estate (6539)
Recruiting (76)
Regulatory (28142)
Reports (62)
Research institute (2704)
Resumes & cover letters (467)
Rett syndrome (34)
RNA editing (23)
RSV (96)
Schizophrenia (180)
Series A (292)
Series B (219)
Service/supplier (25)
Sickle cell disease (115)
Special edition (29)
Spinal muscular atrophy (179)
Sponsored (49)
Startups (4024)
State (2)
Stomach cancer (21)
Supply chain (136)
Tariffs (102)
The Weekly (108)
Vaccines (1217)
Venture capital (108)
Weight loss (515)
Women's health (117)
Worklife (23)
Date
Today (133)
Last 7 days (563)
Last 30 days (2705)
Last 365 days (32080)
2026 (9348)
2025 (32411)
2024 (37585)
2023 (42139)
2022 (53494)
2021 (58266)
2020 (57074)
2019 (50272)
2018 (38194)
2017 (35212)
2016 (35181)
2015 (41107)
2014 (34981)
2013 (30229)
2012 (32390)
2011 (32900)
2010 (31039)
Location
Africa (964)
Alabama (99)
Alaska (7)
Arizona (356)
Arkansas (16)
Asia (45246)
Australia (7691)
California (12864)
Canada (3634)
China (1343)
Colorado (553)
Connecticut (570)
Delaware (387)
Europe (102024)
Florida (1927)
Georgia (419)
Hawaii (4)
Idaho (65)
Illinois (1057)
India (87)
Indiana (593)
Iowa (24)
Japan (518)
Kansas (135)
Kentucky (51)
Louisiana (43)
Maine (75)
Maryland (1588)
Massachusetts (9389)
Michigan (363)
Minnesota (720)
Mississippi (7)
Missouri (155)
Montana (37)
Nebraska (29)
Nevada (144)
New Hampshire (89)
New Jersey (3446)
New Mexico (32)
New York (3407)
North Carolina (1737)
North Dakota (10)
Northern California (6303)
Ohio (388)
Oklahoma (26)
Oregon (51)
Pennsylvania (2582)
Puerto Rico (28)
Rhode Island (53)
South America (1349)
South Carolina (83)
South Dakota (2)
Southern California (5032)
Tennessee (203)
Texas (2062)
United States (46117)
Utah (387)
Vermont (1)
Virginia (323)
Washington D.C. (86)
Washington State (1067)
West Virginia (4)
Wisconsin (144)
Wyoming (2)
795,261 Results for "helsinn therapeutics us inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Helsinn announces European Commission approval of AKYNZEO® Oral Suspension
February 18, 2026
·
2 min read
Press Releases
Helsinn and ESTEVE expand their partnership extending the Distribution and Licence Agreement for AKYNZEO® and ALOXI® to Austria
February 9, 2026
·
4 min read
Press Releases
Helsinn announces new Executive Leadership Team as it celebrates 50 years
January 13, 2026
·
3 min read
Press Releases
Helsinn and MagnaPharm enter long-term agreement for AKYNZEO® and ALOXI® across five Central and Eastern European countries
February 11, 2026
·
4 min read
GLP-1
Lilly, Baseline Investigate GLP-1s’ Potential in Substance Use as Interest Mounts
Accumulating scientific evidence and industry interest from Eli Lilly, Altimmune and startup Baseline Therapeutics is driving further research on the therapeutic potential of GLP-1 receptor agonists in treating substance use disorders.
March 30, 2026
·
6 min read
·
Catherine Offord
Press Releases
Vasomune Therapeutics, Inc., and AnGes, Inc., Announce US FDA Clearance of Investigational New Drug (IND) Application For Pegevongitide (AV-001) Treatment in Resuscitation of Severely Burned Patients
March 4, 2026
·
3 min read
Press Releases
BrYet US, Inc. Files IND Application for ML-016, Lead Oncology Therapeutic for Advanced Solid Tumors with Lung and/or Liver Metastases
March 4, 2026
·
1 min read
Press Releases
Inscobee Inc. and Apimeds, Inc. Reaffirms Appointment of New Board of Directors for Apimeds Pharmaceuticals US, Inc.
March 25, 2026
·
3 min read
Helsinn Group announces AKYNZEO® (fosnetupitant/palonosetron) injection is now available in a ready-to-use vial in the US
Helsinn Group (“Helsinn”), a global pharmaceutical company with a track record of over forty-five years of commercial execution and a strong focus in supportive care, oncology and dermato-oncology, is pleased to announce that AKYNZEO® (fosnetupitant/palonosetron) injection is now available in the US in a ready-to-use vial.
June 24, 2024
·
5 min read
Press Releases
BrYet US, Inc. to Present ML-016 Preclinical Efficacy Data at AACR 2026
Preclinical studies show strong antitumor efficacy in lung metastasis models of triple-negative breast cancer and soft-tissue sarcoma
April 3, 2026
·
1 min read
1 of 79,527
Next
